5 Largest Canadian Cannabis LPs - 13% This Week; -26% In Last 6 Weeks

Image source

To help you with your investment decisions, this article presents

• the stock performance of each of the 5 largest Canadian cannabis licensed producers (LPs) in the munKNEE Canadian Cannabis LPs Index this week and in the last 6 weeks in descending order,
• the average 12-month stock price targets (source) for each constituent according to the analysts that cover these companies,
• the percentage change from today's price,
• the consensus buy, hold and sell recommendations, and
• the percentage chance of encountering financial distress over the next 2 years (source)

 

1. Cronos (CRON): DOWN 11.1% this week and DOWN 22.5% in the last 6 weeks
   • 18 analysts have:
     • an average year-end price target of $1.99 representing
     • a 33.7% increase from the March 10th price of $1.93 and
     • a consensus BUY rating and, according to an analysis by macroaxis.com, has
     • a 3% chance of going through some form of financial distress in the next two years.
2. Tilray (TLRY): DOWN 14.5% this week and DOWN 24.6% in the last 6 weeks
   • 22 analysts have:
     • an average year-end price target of $2.64 representing
     • a 9.1% increase from the March 10th price of $2.42 and
     • a consensus BUY rating and, according to an analysis by macroaxis.com, has
     • a 68% chance of going through some form of financial distress in the next two years.
3. Aurora (ACB): DOWN 11.9% this week and DOWN 27.5% in the last 6 weeks
   • 14 analysts have:
     • an average year-end price target of $1.32 representing
     • a 44.6% increase from the March 10th price of $0.74 and
     • a consensus HOLD rating and, according to an analysis by macroaxis.com, has
     • a 78% chance of going through some form of financial distress in the next two years.
4. OrganiGram (OGI): DOWN 16.5% this week and DOWN 28.3% in the last 6 weeks
   • 15 analysts have:
     • an average year-end price target of $1.50 representing
     • a 107.6% increase from the March 10th price of $0.66 and
     • a consensus BUY rating and, according to an analysis by macroaxis.com, has
     • a 49% chance of going through some form of financial distress in the next two years.
5. Canopy Growth (CGC): DOWN 10.9% this week and DOWN 30.0% in the last 6 weeks
   • 23 analysts have:
     • an average year-end price target of $2.22 representing
     • a 4.9% increase from the March 10th price of $2.05 and
     • a consensus SELL rating and, according to an analysis by macroaxis.com, has
     • a 53% chance of going through some form of financial distress in the next two years.

---

More By This Author:

Ayr Wellness Q4 Financials: Operating Loss Increases; EBITDA Improves
MindMed: Researching LSD And MNMA To Treat Neurological Diseases
Trulieve Q4 Financials: Revenue Static; Net Loss Reduced By 33%